A major contributing factor to the high mortality rate associated with acute myeloid leukemia (AML) and multiple myeloma (MM) is the development of resistance to chemotherapy. Our laboratory has shown that the combination of tipifarnib, a non-peptidomimetic farnesyltransferase inhibitor, with bortezomib, a proteosome inhibitor, promotes synergistic death and overcomes de novo drug resistance in AML cell lines. Experiments were undertaken to identify the molecular mechanisms by which tipifarnib produces cell death in AML and MM 
JPET #172809
3
Abstract:
A major contributing factor to the high mortality rate associated with acute myeloid leukemia (AML) and multiple myeloma (MM) is the development of resistance to chemotherapy. Our laboratory has shown that the combination of tipifarnib, a non-peptidomimetic farnesyltransferase inhibitor, with bortezomib, a proteosome inhibitor, promotes synergistic death and overcomes de novo drug resistance in AML cell lines. Experiments were undertaken to identify the molecular mechanisms by which tipifarnib produces cell death in AML and MM cell lines, U937 and 8226, respectively. Tipifarnib, but not other farnesyltransferase inhibitors tested (FTI-277 and FTI-2153) overload. Preventing Ca 2+ influx diminished tipifarnib-evoked cell death, whereas 2-APB potentiated this effect, demonstrating a link between tipifarnib-induced Ca 2+ influx and apoptosis. These data suggest that tipifarnib exerts its effects by acting on a membrane channel with pharmacological properties consistent with store-operated channels (SOC) containing the Orai3 subunit. Importantly, Orai3 transcripts were found to be expressed at lower levels in tipifarnib resistant 8226/R5 cells. Our results indicate tipifarnib causes cell death via a novel mechanism involving activation of a plasma membrane Ca 2+ channel and intracellular Ca 2+ overload.
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Introduction:
Farnesyltransferase inhibitors (FTIs) are a novel class of anticancer agents developed to inhibit the enzyme farnesyltransferase that is responsible for the transfer of a farnesyl group to the Ras protein. FTIs were originally designed to inhibit Ras oncogenic activity, but recent studies suggest that FTIs may have several other targets including centromeric proteins and the phosphatidylinositide-3 kinase/Akt pathway (Ashar et al., 2000; Jiang et al., 2000) . To date, several FTIs have been clinically evaluated, including BMS-214664, SCH-66363 and R115777
for myelodysplastic syndrome, chronic myelogenous leukemia and acute leukemias (Johnston and Kelland, 2001; Karp et al., 2001; Kurzrock et al., 2003) . Tipifarnib (R115777; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one) is a potent non-peptidomimetic inhibitor of farnesyltransferase (Karp et al., 2001) . Previous studies, including work from our laboratory, have demonstrated the anticancer activity of tipifarnib as a single agent or in combination in preclinical models for multiple myeloma and acute myeloid leukemia (Alsina et al., 2004; Beaupre et al., 2004; Yanamandra et al., 2006) . However, a recent study in which modifications were made to the core structure of tipifarnib to generate novel benzofuran FTIs showed that the antiproliferative properties of the tipifarnib analogs were not exclusively related to their affinity for farnesyltransferase (Asoh et al., 2009 ). Some compounds with high FTI activity exhibited little antiproliferative effects, suggesting that FTI activity is not sufficient to inhibit cancer cell growth (Asoh et al., 2009 ). Thus, the molecular mechanisms by which tipifarnib triggers cell death still remain elusive, and has not been unequivocally associated with farnesyltransferase inhibition.
The adhesion of tumor cells to fibronectin and bone marrow stromal cells has been implicated in the cellular rearrangement of molecules involved in drug resistance including c-FLIP, Topoisomerase IIB, Fas and Bcl-2 (Hazlehurst et al., 2001 uniporter (Landowski et al., 2005) . However, it remains to be determined if tipifarnib acts via an identical mechanism to induce cell death and act synergistically with bortezomib, or if the FTI is targeting a second molecular mechanism which also culminates in the induction of ER stress and concomitant cell death.
In the present study we examined the mechanisms by which tipifarnib induces ER stress and apoptosis in acute myeloid leukemia (U937) and a multiple myeloma (8226) (Manassas, VA). The 8226/R5 line was developed in our laboratory and has been previously described (Buzzeo et al., 2005) . Tumor cell lines were adhered to fibronectin overnight at 37°C
as previously described (Yanamandra et al., 2006) prior to all experiments being carried out, unless otherwise indicated.
Cytotoxicity assays
Cytotoxicity analysis was determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay as previously described (Buzzeo et al., 2005) . For all cytotoxicity studies cells were exposed to both calcium modulating agents and tipifarnib simultaneously for 72 hours. After 72 hours at 37°C, 50μl of MTT (Sigma Chemical) was added to each well and cells were incubated for an additional four hours. All experiments were done in triplicate.
Western blotting
Western blotting was performed as described previously (Beaupre et al., 2003 
Quantitative RT-PCR
Total RNA was isolated from 2x10 6 log-phase cells using the QIAshredder and RNeasy
Mini Kits (Qiagen). Reverse transcription and PCR was done using the Power SYBR Green RNA-to-C T TM 1-step kit (Applied Biosystems) utilizing QuantiTect primers against Hs_GAPDH_2_SG and Hs_ORAI3_1_SG (Qiagen, QT01192646 and QT00231910 respectively). Briefly, 4 ng total RNA was reacted in a 25 μl final volume using 1x final primer concentrations and recommended cycling specifications for SYBR Green on a StepOnePlus
Real-Time PCR machine (Applied Biosystems). Reactions were performed in triplicate for target (ORAI3) and endogenous control (GAPDH) for each cell line. The experiment was repeated three times independently using freshly isolated RNA. All data was compiled and Relative Quantity (RQ) of expression was calculated using the Applied Biosystems algorithm.
Measurement of the Intracellular Calcium
Intracellular free-calcium was measured using the Ca 2+ sensitive dye, fura-2, as we have previously described (DeHaven and Cuevas, 2004) . Cells were plated on coverslips coated with poly-D-lysine (Sigma), which enhances cell adhesion in our model and permits responses to chemotherapeutic agents in leukemia cell lines identical to those obtained with fibronectin (Landowski et al., 2005) . Fura-2 loading was carried out incubating the plated cells for 1 hour at room temperature in physiological saline solution (PSS) consisting of (in mM): 140 NaCl, 3 KCl, 2.5 CaCl 2 , 1.2 MgCl 2 , 7.7 glucose and 10 HEPES (pH to 7.2 with NaOH), which also contained 8 1 μM of the membrane permeable ester form of fura-2, acetoxymethylester (fura-2 AM) and 0.1 % dimethyl sulfoxide (DMSO). The coverslips were then washed in PSS (fura-2-AM free) prior to the experiments being carried out. All drugs were bath applied in PSS.
Reagents
Tipifarnib ( 
Statistical analysis
For multiple group comparisons, one-way or two-way analysis of the variance (ANOVA) tests were carried out, as appropriate. When the ANOVA indicated significant difference, a post-hoc analysis with the Tukey Test was conducted to identify the group or groups that were significantly different. Unless otherwise stated, statistical data are expressed as mean ± standard error.
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Tipifarnib evokes ER stress
We have previously shown that tipifarnib acts synergistically with bortezomib and can overcome CAM-DR in multiple myeloma and acute myeloid leukemia. It has also been suggested that induction of the ER stress response by tipifarnib may be responsible for reversal of the CAM-DR phenotype (Yanamandra et al., 2006) . Experiments were conducted to confirm that tipifarnib induces the ER stress response in leukemia cells using U937 cells. Leukemia cells were adhered onto fibronectin to promote CAM-DR and treated with tipifarnib for 48 hr.
Protein extracts from untreated (Control) and tipifarnib treated U937 cells were probed for expression of procaspase-12, an ER resident caspase that is specifically activated by ER stress (Nakagawa et al., 2000) , and poly adenosine triphosphate polymerase (PARP), a caspase-3 substrate and the indicator of apoptosis (Oliver et al., 1998) . Figure 1A application also resulted in cleavage of caspase-4, a second caspase implicated in the ER stress response (data not shown) (Hitomi et al., 2004) . These data confirm that tipifarnib triggers ER-stress related pathways in adherent leukemia cells.
Intracellular Calcium homeostasis is dysregulated by tipifarnib in U937 leukemia cells
ER stress can be induced by various factors, such as disruption of intracellular Ca 2+ homeostasis (Rao et al., 2004 Figure 2C ). This form of membrane blebbing has been described as membrane "boiling", is specifically associated with apoptotic but not necrotic cell death (Laster et al., 1988) , and is known to be caused by [Ca 2+ ] i overload (Furuya et al., 1994) . Figure 5D ). In 8226/R5 cells the increase was ~250%, and this potentiation changed the amplitude of the response (226 ± 12 nM) such that it was comparable to that seen in 8226 cells in the absence of 2-APB (215 ± 17 nM) ( Figure 5D ).
U937 and 8226 cells express higher levels of Orai3 than 8226/R5 cells
One of the plasma membrane Ca 2+ channels found in U937 cells is the channel mediating the Ca 2+ release-activated Ca 2+ current (I CRAC ) (Wu et al., 1997) . While the results obtained with 2-APB indicate that the conventional I CRAC consisting of Orai1 subunits are unlikely to produce these effects, they raise the possibility that the Orai1 homolog, Orai3, may be involved. Unlike both Orai1 and Orai2, Orai3 channels are not inhibited by 2-APB (DeHaven et al., 2008) , but rather potentiated by the compound even at high concentrations (≥ 100 μM) (DeHaven et al., 2008) . This motivated us to retrospectively analyze gene array data we previously collected on the tipifarnib sensitive cell lines, U937 and 8226, and the tipifarnibresistant, 8226/R5 cells (Buzzeo et al., 2005; Hazlehurst et al., 2006) . Figure 6A shows a bar graph of the results obtained and indicates a trend of Orai3 being expressed at lower levels in Moreover, mRNA transcripts for this SOC subunit are expressed at higher levels in tumor cell lines which have greater sensitivity to tipifarnib.
Previously we have shown that both tipifarnib and bortezomib as single agents and in combination overcome cell adhesion mediated drug resistance and induce ER-stress in multiple myeloma and acute myeloid leukemia cells (Buzzeo et al., 2005; Yanamandra et al., 2006) . Our data show that that tipifarnib, as a single agent, processed caspase-12, an ER resident caspase in a dose dependent manner ( Figure 1A shown to have cellular effects (Lerner et al., 1995; Sun et al., 1999) (Figure 2B ), suggesting that inhibition of farnesyltransferase alone is not sufficient to elicit the [Ca 2+ ] i overload. Interestingly, the FTI, perillyl alcohol, has also been shown to elevate Ca 2+ , induce membrane boiling and promote apoptosis in activated T lymphocytes (Wei et al., 2000) . The effects of perillyl alcohol on T lymphocyte, however, were biphasic and more rapid than those reported here for tipifarnib (< 1 min Several studies have linked apoptosis to calcium signaling pathways as a response to cellular stress (Orrenius et al., 2003) . ER stress induces apoptosis via two different mechanisms, the unfolded protein response and dysregulation of Ca 2+ homeostasis (Ferri and Kroemer, 2001; Lee et al., 2002) . Our findings that agents which inhibit or potentiate tipifarnibinduced [Ca 2+ ] i overload diminish or enhance the apoptosis promoted by this drug, respectively, indicate that this influx of Ca 2+ through the plasma membrane is directly linked to the influence of tipifarnib on cell survival. Moreover, the plasma membrane "boiling" observed here is known to be triggered by [Ca 2+ ] i overload and is a marker for apoptotic cell death (Laster et al., 1988; Furuya et al., 1994) . Such membrane blebbing was not observed in the absence of extracellular Ca 2+ or when lanthanides were applied.
Several plasma membrane calcium channels have been identified in U937 cells that may potentially account for the elevations in [Ca 2+ ] i and concomitant cell death reported here in response to tipifarnib application. These channels include TRPM2, TRPM7 and store-operated calcium channels (Willmott et al., 1996; Lee et al., 2006; Zhang et al., 2006) . In U937 cells, activation of TRPM2 with either H 2 O 2 or TNF-α increased cleavage of caspase-8, -9, -3 and -7
and PARP, and consequently, cell death was enhanced in a [Ca 2+ ] i -dependent manner (Zhang et al., 2006) . However, TRPM2 channels are not inhibited by concentrations of La 3+ ≤ 100 μM (Kraft et al., 2004) , and low concentrations of this trivalent cation blocked both the Ca 2+ increases and cell death evoked by tipifarnib in our study. Furthermore, a recent study suggests that TRPM2 channels heterologously expressed in HEK-293 cells are blocked by 2-APB with an IC 50 of 1 μM (Togashi et al., 2008) . Thus, the pharmacological properties of the tipifarnib-activated conductance are not consistent with TRPM2.
Like TRPM2, TRPM7 is activated by H 2 O 2 and is believed to be involved in oxidative stress-induced cell death. Overexpression of TRPM7 in HEK-293 cells results in cell swelling, detachment and death (Nadler et al., 2001) . In cortical neurons, siRNA-mediated depression of TRPM7 expression protected cells form anoxic cell death (Aarts and Tymianski, 2005) .
However, 10 μM La 3+ and Gd 3+ failed to inhibit TRPM7 channels heterologously expressed in HEK-293 cells (Monteilh-Zoller et al., 2003) , and 1 mM concentrations of these ions was required to inhibit TRPM7. Thus, the tipifarnib-activated Ca 2+ conductance does not share these properties with TRPM7, since 200 nM La + was sufficient to abolish both the Ca 2+ elevations and the cell death evoked by the FTI and 100 μM Gd 3+ produced a near complete block of the Ca 2+ increase. Also, 100 μM 2-APB blocks ~25% of TRPM7-evoked currents (Li et al., 2006) , but fails to decrease the Ca + elevations or U937 cell death evoked by tipifarnib.
To date, there is little evidence linking the activation of store-operated calcium channels and cell death. A recent study on cervical epithelial cells indicates that soft substrate-induced apoptosis is mediated by the interaction of the calcium sensor, stromal interacting molecule 1 (STIM1), and the pore-forming subunit (Orai1) of store-operated calcium channels (Chiu et al., 2008) . Upon contact with soft substrate, SOC activity is upregulated and Ca 2+ homeostasis disturbed in normal cervical epithelial cells, which in turn triggers a pro-apoptotic signaling cascade involving μ-calpain (Chiu et al., 2008) . Interestingly, the activation of SOC is depressed in malignant cervical epithelial cells, and these cells do not undergo soft-substrateinduced apoptosis (Chiu et al., 2008) . The inhibition of tipifarnib-induced Ca 2+ influx by La 3+ and Gd 3+ is consistent with an Orai1-containing SOC-mediated phenomenon. However, Orai1-containing SOC are inhibited by 100 μM 2-APB, and thus the activation the potentiation of tipifarnib effects by this drug is inconsistent with an Orai1-mediated effect. Unlike Orai1-containing channels, the related SOC subunit, Orai3 has been shown to form functional SOC that are potentiated by 2-APB (DeHaven et al., 2008) . Gene array data and qRT-PCR experiments conducted here confirm that Orai3 is expressed in both U937 and 8226 cells. with tipifarnib potentiates the effects of tipifarnib on the resistant 8226/R5 cells, indicating that greater tipifarnib sensitivity may be conferred in this manner. Interestingly, a recent study on breast cancer cell lines found that Orai3-containing channels are expressed at higher levels in estrogen receptor positive cells relative to estrogen receptor negative tumor cells (Motiani et al., 2010) . These channels were also functionally identified on the basis of 2-APB sensitivity, with
Orai3 expressing cells having SOC responses potentiated by the drug. However, the capacity of these Orai3 channels to influence cell survival was not addressed in that study, nor was the sensitivity of these channels to chemotherapeutic agents assessed.
In conclusion, in this study, we identify a novel mechanism by which tipifarnib induces ER stress in U937 leukemia cells. 
